Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ginisortamab in Advanced Solid Tumors
NCT04393298Phase 2Completed
- Sponsor
- UCB
- Start
- Jul 2020
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label trial of ginisortamab in colorectal adenocarcinoma, esophageal carcinoma, head and neck squamous cell carcinoma (HNSCC) and 8 more (4 arms), sponsored by UCB. Primary endpoints: Percentage of Participants With Treatment-emergent Adverse Events up to 3.8 years, Percentage of Participants Based on Severity of Treatment-emergent Adverse Events up to 3.8 years and 1 more. Started Jul 2020; status: completed.
02
Drugs
ginisortamab
03
Conditions
colorectal adenocarcinomaesophageal carcinomahead and neck squamous cell carcinoma (HNSCC)lung adenocarcinomasquamous cell carcinoma of the lung (LSCC)
Beyond the preview
Go deeper on NCT04393298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04393298.